Curevac initiates strategic restructuring to align resources with focus on high-value mrna pipeline opportunities

Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mrna technology to develop novel treatment approaches company expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at least two new phase 1 studies by the end of 2026 cash runway extended into 2028 through combination of new licensing agreement with gsk, reduced operating expenses and enhanced financial discipline tÜbingen, germany and boston, ma / accesswire / july 3, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced a significant strategic restructuring to focus its resources on high-value mrna projects in oncology and other select areas of substantial unmet medical need.
CVAC Ratings Summary
CVAC Quant Ranking